Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on May 02, 2021 10:20pm
123 Views
Post# 33112190

RE:RE:RE:RE:Capital Market and Proxy Notes

RE:RE:RE:RE:Capital Market and Proxy Notes

you are also right on the earnings calls.  Until such time they get more engaged analysts, they should open it up to prior requested email questions compiled into general topics by someone there.  


palinc2000 wrote: Wino
You deserve a lot of credit for the time you spent on this task of representing a lot of shareholders and reporting back .Your highly  professional way in the way you approached and carried out your discussion with the Chairwoman and the CeO is noteworthy.

I gather that they agreed to this meeting on the condition that you submit your questions a week in advance...I sense that some if not most of the answers  are really just politically correct and aimed at not getting any nominee (s)
on the Slate rejected by shareholders that you represent...
I am not sure that we should just  simply give them a free pass 
My proposal would be for you to  be allowed to ask questions at all Q&A periods during CC s where analysts are invited  .... You would be the sole judge of which questions to ask and not be bound by allegiance to this Stockhouse MB.... 
If the Company agrees formally or informally  before the deadline to submit the Proxys to allow you to ask questions LIVE  then I think we could give them a free pass on the Slate .Otherwise I think we should proceed as planned and vote to remove one or more nominees.






Sent from my iPhone

 

<< Previous
Bullboard Posts
Next >>